Please login to the form below
Data by
Top 25 pharma companies by cardiovascular sales
The rankings of the top 25 pharmaceutical companies in cardiovascular have been compiled from GlobalData's pharmaceutical revenue figures, which are based on sales of prescription medicines, including generics drugs. The rankings include figures for 2014, 2013, 2012 and 2011.
For ease of comparison the rankings, along with those for CNS, immunology, oncology, metabolic, global, US and Japan sales, are also displayed in the Top Pharma List 2012 infographic.
| # | Company | 2014 ($m) | 2013 ($m) | Growth ($m) | Growth (%) |
|---|---|---|---|---|---|
| 1 | AstraZeneca | 7657 | 7723 | -66 | -1 |
| 2 | Sanofi | 6620 | 6850 | -230 | -3 |
| 3 | Merck & Co. | 5230 | 5794 | -564 | -10 |
| 4 | Daiichi Sankyo | 4665 | 5205 | -540 | -10 |
| 5 | Pfizer | 4125 | 4603 | -478 | -10 |
| 6 | Novartis | 3948 | 5270 | -1322 | -25 |
| 7 | Bayer | 3868 | 2800 | 1068 | 38 |
| 8 | Takeda | 2457 | 2324 | 133 | 6 |
| 9 | Boehringer Ingelheim | 2418 | 3314 | -896 | -27 |
| 10 | Astellas | 2029 | 2105 | -76 | -4 |
| 11 | Actelion | 1958 | 1795 | 163 | 9 |
| 12 | Johnson & Johnson | 1522 | 864 | 658 | 76 |
| 13 | Shionogi | 1297 | 1512 | -215 | -14 |
| 14 | United Therapeutics | 1280 | 1107 | 173 | 16 |
| 15 | Bristol-Myers Squibb | 1193 | 635 | 558 | 88 |
| 16 | Gilead Sciences | 1105 | 969 | 136 | 14 |
| 17 | Otsuka | 846 | 817 | 29 | 4 |
| 18 | Roche | 796 | 728 | 68 | 9 |
| 19 | Lilly | 705 | 695 | 10 | 1 |
| 20 | The Medicines Company | 674 | 625 | 49 | 8 |
| # | Company | 2013 ($m) | 2012 ($m) | Growth ($m) | Growth (%) |
|---|---|---|---|---|---|
| 1 | AstraZeneca | 7723 | 8750 | -1027 | -12 |
| 2 | Novartis | 7215 | 7476 | -261 | -3 |
| 5 | Pfizer | 5735 | 8039 | -2304 | -29 |
| 3 | Sanofi | 6448 | 7337 | -889 | -12 |
| 4 | Merck & Co. | 6129 | 6576 | -447 | -7 |
| 6 | Daiichi Sankyo | 4053 | 4165 | -112 | -3 |
| 7 | Boehringer Ingelheim | 3926 | 3509 | 417 | 12 |
| 24 | Bristol-Myers Squibb | 635 | 3052 | -2417 | -79 |
| 12 | Astellas | 2006 | 2116 | -110 | -5 |
| 11 | GlaxoSmithKline | 2144 | 2266 | -122 | -5 |
| 18 | AbbVie | 953 | 2301 | -1348 | -59 |
| 10 | Takeda | 2500 | 2428 | 72 | 3 |
| 9 | Bayer | 2579 | 1887 | 692 | 37 |
| 14 | Shionogi | 1463 | 1476 | -13 | -1 |
| 16 | United Therapeutics | 1107 | 907 | 200 | 22 |
| 20 | Otsuka | 835 | 808 | 27 | 3 |
| 17 | Gilead Sciences | 969 | 783 | 186 | 24 |
| 22 | Dainippon Sumitomo Pharma | 719 | 755 | -36 | -5 |
| 23 | Mitsubishi Tanabe | 695 | 724 | -29 | -4 |
| 21 | Roche | 728 | 623 | 105 | 17 |
| 25 | The Medicines Company | 625 | 558 | 67 | 12 |
| 8 | Lilly | 3105 | 2823 | 282 | 10 |
| 13 | Actelion | 1794 | 1743 | 51 | 3 |
| 15 | Biogen Idec | 1126 | 1138 | -12 | -1 |
| 19 | Johnson & Johnson | 864 | 239 | 625 | 262 |
| # | Company | 2012 ($m) | 2011 ($m) | Growth ($m) | Growth (%) |
|---|---|---|---|---|---|
| 1 | AstraZeneca | 8750 | 9605 | -855 | -9 |
| 2 | Novartis | 7548 | 8405 | -857 | -10 |
| 3 | Pfizer | 7505 | 13437 | -5932 | -44 |
| 4 | Sanofi | 7337 | 8454 | -1117 | -13 |
| 5 | Merck & Co. | 6576 | 7174 | -598 | -8 |
| 6 | Daiichi Sankyo | 4165 | 4147 | 18 | 0 |
| 7 | Boehringer Ingelheim | 3509 | 3091 | 418 | 14 |
| 8 | Bristol-Myers Squibb | 3052 | 8039 | -4987 | -62 |
| 9 | Astellas | 2781 | 3011 | -230 | -8 |
| 10 | GlaxoSmithKline | 2377 | 2424 | -47 | -2 |
| 11 | AbbVie | 2301 | 2668 | -367 | -14 |
| 12 | Takeda | 2182 | 2713 | -531 | -20 |
| 13 | Bayer | 2153 | 1821 | 332 | 18 |
| 14 | Shionogi | 1476 | 1512 | -36 | -2 |
| 15 | Amgen | 950 | 808 | 142 | 18 |
| 16 | United Therapeutics | 907 | 741 | 166 | 22 |
| 17 | Otsuka | 854 | 834 | 20 | 2 |
| 18 | Gilead Sciences | 783 | 613 | 170 | 28 |
| 19 | Dainippon Sumitomo Pharma | 755 | 820 | -65 | -8 |
| 20 | Mitsubishi Tanabe | 724 | 777 | -53 | -7 |
| 21 | Roche | 623 | 511 | 112 | 22 |
| 22 | The Medicines Company | 558 | 485 | 73 | 15 |
| 23 | Merck KGaA | 488 | 552 | -64 | -12 |
| 24 | Lilly | 457 | 303 | 154 | 51 |
| 25 | Forest Laboratories | 455 | 348 | 107 | 31 |
Note: The 2013 ranking uses 2013 exchange rates for both its 2013 and 2012 values, to remove the effect of currency fluctuations. The 2012 ranking similarly uses 2012 exchange rates.
Data by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
Featured jobs
-
*Design Manager*
-
Competitive Salary
- Account Manager, Healthcare PR, Global and UK
-
£33, 000 – £40, 000
- Senior Corporate Communications Manager
-
Competitive Salary
- Senior Director, Healthcare PR, Home Counties
-
Competitive
- Senior Account Manager – Healthcare PR
-
Salary TBC
-
Scientific Director
-
£70, 000 - £85, 000
-
Director – Healthcare PR/ Policy
-
Salary TBC
-
Account Director - Med Comms
-
Great salary and benefits
- Account Director - Healthcare Advertising - London
-
£50000 - £68000
-
Head of Marketing Insulin
-
Competitive Salary
-
Principal Medical Writer
-
Great salary and benefits
- Account Manager, Medical Communications
-
£30, 000-£40, 000
-
Senior Medical Writer
-
Great salary and benefits
- Account Director or Senior Account Director, Healthcare Advertis...
-
£55, 000 - £65, 000 benefits
- 6-12 MONTH FREELANCE OPPORTUNITY - ACCOUNT DIRECTOR or SENIOR AC...
-
SUPERB DAY RATE AVAILABLE
-
*Multi-Channel Creative Designer*
-
Competitive Salary
- FREELANCE *Client Service/ Project Manager*
-
Competitive Salary
-
Brand Communications Manager
-
A competitive salary plus bonus
Subscribe to our email news alerts
- Bayer wins FDA approval for MS electronic autoinjector and app
- Sanofi continues pharma's trend of ditching the corporate blog
- Merck suspends two Keytruda trials after patient deaths
- NICE relents on Kadcyla after Roche pricing negotiations
- Facing the new wave of biosimilars
- Warning sounded on pharma's long-term sales prospects
- How to plan, execute and refine an excellent congress experience
- Jo Fearnhead-Wymbs A year in the role as patient engagement director
- Shire claims FDA approval for slow-cooked ADHD drug
- GSK makes case for revaccination with Shingrix
- Sanofi continues pharma's trend of ditching the corporate blog
- Rapid Payer Response for Manufacturers
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- How to plan, execute and refine an excellent congress experience
- Medical congresses are one of the most important and intensive marketing activities a company can undertake. Here, Account Director Dolan Desai and Senior Creative Copywriter Dale Choate give you the...
- Jo Fearnhead-Wymbs A year in the role as patient engagement director
- A year of patient-cenricity… helping our clients have an even greater impact on patient outcomes...
- Launch Sequencing Case Study
- ...
Quick links
Infographics
